Clinical Time and Temporal Dynamics Study (CLIN-TIME)

TH-CLINICAL-TIME is a prospective longitudinal observational research study designed to investigate the role of temporal dynamics in clinical medicine. The fundamental premise is that a clinical measurement may have different significance depending on its relationship to a patient's prior measurements, the direction and rate of change, the duration of an observed abnormality, the sequence of preceding or subsequent observations, and the patient's subsequent recovery or deterioration.

The study will establish longitudinal research datasets that permit evaluation of individual and population-level clinical trajectories. Depending on the participating cohort and available clinical data, observations may include vital signs, physiologic measurements, electrocardiographic information, cardiovascular measurements, point-of-care ultrasound or other imaging-derived measurements, laboratory results, symptoms, medications, procedures, healthcare encounters, patient-reported outcomes, and appropriately governed remote or digital health measurements.

A principal research objective is to determine whether time-dependent clinical features provide incremental information beyond conventional point-in-time measurements. Investigational temporal features may include baseline deviation, velocity of change, acceleration or deceleration, persistence, variability, recurrence, temporal sequence, time between clinically relevant observations, and recovery kinetics.

The study will investigate the concept of an individualized Clinical Temporal Phenotype, representing the longitudinal behavior of selected clinical variables rather than a single measurement. Individualized analyses may compare a participant's current observations with their own longitudinal baseline as well as with appropriate population reference distributions.

The research program may evaluate whether temporal patterns are associated with predefined clinical outcomes, including clinically meaningful deterioration, hospitalization, emergency evaluation, cardiovascular events, procedure-related outcomes, recovery characteristics, readmission, or other protocol-defined outcomes. Specific endpoints, populations, data sources, analytic methods, and follow-up schedules will be prespecified in the applicable study protocol and statistical analysis plan.

Where appropriate, longitudinal statistical and computational methods may be used to evaluate trajectories and dynamic prediction. These may include longitudinal regression, survival analysis, time-dependent modeling, recurrent-event analysis, joint longitudinal-survival models, dynamic risk prediction, and machine-learning methods. Any predictive models will be evaluated using appropriate temporal validation methods designed to prevent incorporation of future information into predictions of earlier events.

An additional research objective is to evaluate clinical lead time, defined as the interval between identification of a prespecified research signal and a subsequently documented clinical event or clinical recognition point. Research analyses may also evaluate whether recovery kinetics, recurrent deviations, or accelerating changes contain prognostic information.

Remote and digital data may be incorporated when specifically permitted by the study protocol, participant authorization, applicable privacy requirements, and institutional policies. Research-generated alerts or analytical signals will not independently constitute clinical diagnoses or treatment recommendations unless a separately authorized clinical-care process exists.

The study has a planned 50-year study-level horizon from 2026 through 2076 to permit investigation of long-term longitudinal patterns. The study horizon does not imply that every participant will be followed continuously for 50 years. Individual participation and follow-up duration will be governed by the approved protocol, informed consent or other applicable authorization, participant withdrawal, availability of follow-up data, and applicable institutional and regulatory requirements.

The study will employ coded research identifiers and appropriate data-governance procedures. Direct participant identifiers will be maintained separately from research datasets to the extent required by the applicable protocol and institutional policies. Research data will be subject to appropriate access controls, auditability, security safeguards, quality-control procedures, and retention and disposition requirements.

The study is observational and does not, by itself, assign participants to an experimental drug, biologic, or device intervention. Any clinical care received by participants remains under the direction of their treating healthcare professionals and is not altered solely by participation in the observational research unless separately specified in an approved protocol.

The overarching scientific objective is to determine whether clinical time itself can be characterized as a measurable dimension of patient state, and whether longitudinal trajectories, rather than isolated observations, can yield reproducible research biomarkers of clinical change, deterioration, and recovery.

Inclusion criteria

• Adults aged 18 years or older.
• Able and willing to provide informed consent, when informed consent is required by the approved study protocol and applicable regulations.
• Willing and able to participate in longitudinal collection or evaluation of clinical, physiologic, laboratory, imaging-derived, patient-reported, or remote/digital health information as applicable to the study protocol.
• Ability to complete the protocol-defined follow-up schedule or provide sufficient longitudinal observations for analysis.
• Individuals with or without established medical conditions may be eligible, provided their participation is consistent with the study protocol.
• Availability of sufficient baseline information or measurements to establish an individualized reference state when required for the applicable analysis.

Exclusion criteria

• Inability to provide informed consent when consent is required and no legally authorized representative process is applicable.
• Inability to comply with protocol-defined data collection or follow-up requirements.
• Circumstances that, in the judgment of the investigator, would prevent reliable longitudinal data collection or interpretation.
• Enrollment in another research protocol that would materially interfere with participation or interpretation of the outcomes, when applicable.
• Any other exclusion criterion specifically identified in the IRB/ethics-approved protocol.